More and more research is pointing to covid being
Post# of 155141
(Total Views: 593)
Posted On: 04/27/2020 2:27:22 PM
More and more research is pointing to covid being very similar to HIV, that is how CYDY got started with leronlimab, then they moved to cancer, and now full circle back to covid (which is similar to HIV). Ya can't make this up....
The conf call is a must listen when it gets posted for replay
This is very interesting....
<<The investigation of the roles played by CCL5/CCR5 in tumor development and metastasis is only in its infancy. While promalignancy effects are strongly implicated in MM and breast cancer, their contribution to other malignancies such as cHL, melanoma, gastric, prostate, and ovarian and colon cancer deserves further studies.
Furthermore, one has to take into account the fact that the CCL5/CCR5 axis acts in conjunction with other chemokines to affect the malignant phenotype (e.g., the CXCL12/CXCR4 pair), exemplifying the multifactorial nature of malignancies and the need to target several mediators simultaneously. Also, in considering CCL5/CCR5 as therapeutic targets, we should evaluate the effects of anti-CCL5/CCR5 treatments on the immune integrity of the host. The optimal therapeutic modalities would have to accommodate two opposing demands: the need to inhibit the detrimental involvement of CCL5 and CCR5 in specific malignant diseases protecting their potentially beneficial activities in immunity, including the anticancer immune responses.
Overall, our current knowledge leads us to suggest the CCL5/CCR5 axis as a potential therapeutic target in several cancer diseases.>>
https://www.hindawi.com/journals/mi/2014/292376/
The conf call is a must listen when it gets posted for replay
This is very interesting....
<<The investigation of the roles played by CCL5/CCR5 in tumor development and metastasis is only in its infancy. While promalignancy effects are strongly implicated in MM and breast cancer, their contribution to other malignancies such as cHL, melanoma, gastric, prostate, and ovarian and colon cancer deserves further studies.
Furthermore, one has to take into account the fact that the CCL5/CCR5 axis acts in conjunction with other chemokines to affect the malignant phenotype (e.g., the CXCL12/CXCR4 pair), exemplifying the multifactorial nature of malignancies and the need to target several mediators simultaneously. Also, in considering CCL5/CCR5 as therapeutic targets, we should evaluate the effects of anti-CCL5/CCR5 treatments on the immune integrity of the host. The optimal therapeutic modalities would have to accommodate two opposing demands: the need to inhibit the detrimental involvement of CCL5 and CCR5 in specific malignant diseases protecting their potentially beneficial activities in immunity, including the anticancer immune responses.
Overall, our current knowledge leads us to suggest the CCL5/CCR5 axis as a potential therapeutic target in several cancer diseases.>>
https://www.hindawi.com/journals/mi/2014/292376/
(3)
(0)